{"id":40508,"date":"2026-07-22T10:05:54","date_gmt":"2026-07-22T08:05:54","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/?p=40508"},"modified":"2026-07-21T12:53:43","modified_gmt":"2026-07-21T10:53:43","slug":"ez-pave-studie-zu-optimalen-ldl-cholesterinwerten-cme","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2026\/ez-pave-studie-zu-optimalen-ldl-cholesterinwerten-cme","title":{"rendered":"Ez-PAVE-Studie zu optimalen LDL-Cholesterinwerten [CME]"},"content":{"rendered":"<p>Im M\u00e4rz wurde im N. Engl. J. Med. eine Studie zu Zielwerten f\u00fcr das LDL-Cholesterin ver\u00f6ffentlicht, die wir schon mehrfach gefordert haben. Wissenschaftler aus S\u00fcdkorea haben nun in der offen durchgef\u00fchrten Ez-PAVE-Studie zwei Zielwerte f\u00fcr das LDL-Cholesterin bei Patienten mit manifester atherosklerotischer Herz-Kreislauf-Krankheit verglichen: &lt;\u00a055\u00a0mg\/dl (1,4\u00a0mmol\/l) vs. &lt;\u00a070\u00a0mg\/dl (1,8\u00a0mmol\/l). Der niedrigere Zielwert wird von der [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Im M\u00e4rz wurde im N. Engl. J. Med. eine Studie zu Zielwerten f\u00fcr das LDL-Cholesterin ver\u00f6ffentlicht, die wir schon mehrfach gefordert haben. Wissenschaftler aus S\u00fcdkorea haben nun in der offen durchgef\u00fchrten Ez-PAVE-Studie zwei Zielwerte f\u00fcr das LDL-Cholesterin bei Patienten mit manifester atherosklerotischer Herz-Kreislauf-Krankheit verglichen: &lt;\u00a055\u00a0mg\/dl (1,4\u00a0mmol\/l) vs. &lt;\u00a070\u00a0mg\/dl (1,8\u00a0mmol\/l). Der niedrigere Zielwert wird von der [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[684,495,1272,6402,2879,71,453,498,456,65,1522,6403,443],"class_list":["post-40508","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-akutes-koronarsyndrom","tag-angina-pectoris","tag-arteriosklerose","tag-ez-pave-studie","tag-ezetimib","tag-herzinfarkt","tag-hypercholesterinaemie","tag-koronare-herzkrankheit","tag-lipidsenker","tag-myokardinfarkt","tag-pcsk9-hemmer","tag-precise-ivus-studie","tag-statine"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/40508","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=40508"}],"version-history":[{"count":6,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/40508\/revisions"}],"predecessor-version":[{"id":40515,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/40508\/revisions\/40515"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=40508"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=40508"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=40508"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}